We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Federal Judge Issues Ruling in Patent Rights Case

MADISON, WISCONSIN (September 13, 2012)

Today, in the United States District Court for the Western District of Wisconsin, Judge Barbara Crabb entered a judgment overruling a February 2012 jury verdict in favor of Promega. The ruling leaves intact the Court's prior holding that sales by Life Technologies of Short Tandem Repeat (STR) products for use in clinical and research applications in the United States would violate Promega's patents.

In November 2011, the Court's ruling on Summary Judgment affirmed the validity of Promega's STR patents, and found direct infringement by Life Technologies due to its sale of STR kits. After the trial in February 2012, a jury awarded $52 million in damages to Promega, and found the infringing sales were made willfully by Life Technologies. The Court today held that, in spite of the jury's verdict, Promega had not sufficiently proven certain elements of its damages claim against Life Technologies. The Court, however, did not overrule the holding by the jury that Life Technologies' actions were willfully undertaken and might thereby be subject to trebling, and did not overrule the Court's prior findings that Life Technologies' sales in clinical and research applications infringed Promega's patents. The Court dismissed all of Life Technologies' remaining defenses and claims against Promega.

"Nothing about today's ruling affects Promega's long and continuing commitment to provide high quality products and support to the life sciences market, including STR products for use in all applications. Nor does it impact our intent to continue to enforce our STR patents against those who illegally sell STR products to clinical and research customers," says Bill Linton, Promega CEO. "While we are disappointed with the Court's decision today, we are considering all available options to continue to pursue what we believe are valid claims against Life Technologies' actions in the STR market. In spite of this ruling, we remain encouraged that a jury of citizens found in our favor earlier this year."

This ruling leaves significant issues unresolved, including, but not limited to, enjoining further infringing sales of STR products by Life Technologies in the United States and remedying damages suffered by Promega for past and potentially continuing infringing sales in the United States.

Additional product information on Promega STR analysis products is located at: http://www.promega.com/products/str-analysis/

Promega's pioneering STR technology is used worldwide in a number of applications for genetic analysis beyond forensics and paternity testing, including genetic research, cell line authentication, bone marrow transplantation monitoring, forensic training, and various types of cancer analysis.

About Promega

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA, with branches in 15 countries and over 50 global distributors. For more information about Promega, visit: www.promega.com

These pages contain communications on Promega product releases and corporate activities. For additional new product information, see the new products page or the specific product or application area.

For more information about a press release or about Promega in general, contact Promega Corporate Affairs at 1-608-274-4330 or via our contact page.

Choose your country


United States

Pacific Asia

Korea, Republic of


United Kingdom